3.9 Review

Metastasis in renal cell carcinoma: Biology and implications for therapy

Journal

ASIAN JOURNAL OF UROLOGY
Volume 3, Issue 4, Pages 286-292

Publisher

ELSEVIER SINGAPORE PTE LTD
DOI: 10.1016/j.ajur.2016.08.006

Keywords

Renal cell carcinoma; Metastasis; Vascular endothelial growth factor; Mammalian target of rapamycin; Hypoxia inducible factor

Funding

  1. Pfizer
  2. Novartis
  3. Aveo
  4. Genentech
  5. Exelixis
  6. BMS
  7. Astellas
  8. GSK

Ask authors/readers for more resources

Although multiple advances have been made in systemic therapy for renal cell carcinoma (RCC), metastatic RCC remains incurable. In the current review, we focus on the underlying biology of RCC and plausible mechanisms of metastasis. We further outline evolving strategies to combat metastasis through adjuvant therapy. Finally, we discuss clinical patterns of metastasis in RCC and how distinct systemic therapy approaches may be considered based on the anatomic location of metastasis. (C) 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available